Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts have an average recommendation of "Hold" on Coherus Oncology (1 sell, 1 hold, 3 buy) with a mean 1‑year target of $5.51.
• The company missed its latest quarter—EPS of ($0.34) vs. ($0.31) expected and revenue $12.75M vs. $14.09M—and analysts forecast roughly -1.05 EPS for the current fiscal year.
• Shares trade around $1.67 (1‑year range $0.71–$2.62) with a market cap near $250M and 72.82% institutional ownership; Coherus commercializes biosimilars including Udenyca and Fulphila.

Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $5.5125.

CHRS has been the subject of several research reports. Wall Street Zen raised Coherus Oncology from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Oppenheimer initiated coverage on Coherus Oncology in a report on Thursday, January 22nd. They set an "outperform" rating and a $10.00 price target for the company.

Institutional Investors Weigh In On Coherus Oncology

Several hedge funds have recently added to or reduced their stakes in CHRS. Quarry LP acquired a new stake in Coherus Oncology during the 3rd quarter valued at $26,000. Blair William & Co. IL acquired a new stake in Coherus Oncology during the 4th quarter valued at $27,000. Bronte Capital Management Pty Ltd. acquired a new stake in Coherus Oncology during the 4th quarter valued at $27,000. China Universal Asset Management Co. Ltd. acquired a new stake in Coherus Oncology during the 4th quarter valued at $28,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in shares of Coherus Oncology during the fourth quarter worth $28,000. Institutional investors and hedge funds own 72.82% of the company's stock.

Coherus Oncology Price Performance

NASDAQ:CHRS opened at $1.67 on Tuesday. Coherus Oncology has a 1-year low of $0.71 and a 1-year high of $2.62. The company has a current ratio of 1.47, a quick ratio of 1.45 and a debt-to-equity ratio of 0.61. The firm has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $1.61. The stock has a market capitalization of $250.32 million, a PE ratio of 1.14 and a beta of 1.03.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. The business had revenue of $12.75 million for the quarter, compared to analyst estimates of $14.09 million. On average, research analysts expect that Coherus Oncology will post -1.05 EPS for the current fiscal year.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company's lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen's Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.